NY-CLARITY-AI
17.3.2022 18:06:12 CET | Business Wire | Press release
The EU Taxonomy aims to align all market stakeholders on what is considered sustainable in the context of the EU, but investors need greater transparency on just how green the funds they are buying really are. Analysis by Clarity AI, the market-leading, global sustainability technology platform, reveals significant differences between fund revenues aligned with green – and EU Taxonomy related – objectives across different types of sustainable investment products in the market today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005718/en/
Under the Sustainability Finance Disclosure Regulation (or SFDR), investors need to report the EU Taxonomy alignment as part of the sustainability profile of funds, which need to be classified into one of three categories:
- Article 6: non-sustainable funds
- Article 8: funds that promote sustainable characteristics but not as an overarching objective
- Article 9: funds that have been specifically created to address sustainability goals
In a whitepaper titled “EU Taxonomy: Using Tech to Analyze ‘Green’ Fund Performance,” Clarity AI analyzed an investable universe of 31,000 equity funds on how these products perform against new EU Taxonomy requirements and assessed the common traits across funds, which are often branded in some way as “green.” The analysis shows that:
- Globally, 3.6% of revenues can be considered green (“green revenues”) – that is, they contribute to mitigating climate change.
- Only 7% of the 31,000 equity funds analyzed have more than 10% green revenues, as defined in the EU taxonomy.1
- Article 9 climate-branded funds present four times higher alignment with the EU taxonomy than the overall sample average, with 15% of revenues classified as green. Article 8 funds, however, have a similar alignment to the average, with 3.9% green revenues.
- Funds focused on sectors that are doing heavy lifting in the green transition, such as utilities, show a higher exposure and alignment, with 25% green revenues.
- Funds with equity themes, such as alternative energy, are naturally more aligned with a green economy, with up to 27% green revenues.
Patricia Pina, Head of Product Research & Innovation at Clarity AI, said: “Considering the disparate definitions of and frameworks for sustainability all around the world, we can look to the EU Taxonomy as a pioneer in setting a common standard to align a large segment of global market stakeholders. At Clarity AI, we believe regulation needs to be supported by detailed, data-led insights, and transparency cannot be a nice-to-have. It is a must-have.
“The EU recognizes that a key requirement to further the development of the sustainable investment market is ‘access to high-quality sustainability-related data.’ 2 This high-quality data also means moving away from subjectivity and using an objective and fact-based definition of what should be considered ‘green,’ ‘social,’ ‘environmental,’ and so on. The EU taxonomy gives us a common language that will enable stronger decision making and an acceleration to a more sustainable economy.
“Reliable, transparent insights are at the heart of fact-based sustainable finance. They should become the norm in making informed decisions around ‘green’ investing.”
Notes to editors
About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors and organizations. As of December 2021, Clarity AI’s platform analyzes more than 30,000 companies, 180,000 funds, 198 countries and 187 local governments, and delivers data and analytics for investing, corporate research and reporting. Clarity AI has offices in the US, Europe, and the Middle East. Clarity AI’s client network manages trillions in assets under management. clarity.ai
Methodology
Clarity AI developed a comprehensive assessment of how companies and funds align with the EU Taxonomy classification of sustainability using its proprietary sustainable analytics technology platform. Clarity AI draws on the broadest possible spectrum of tools and data sources available to increase the coverage, precision and objectivity of the sustainability analysis, while remaining transparent. The method in this paper relies on the three steps of Clarity AI's EU Taxonomy analysis and displays two key metrics that investors will need to report:
- % Eligible green revenue: as defined by revenues exposed to the activities outlined in the EU Taxonomy
- % Aligned green revenue: which builds upon eligible activities and embeds an assessment of the technical screening criteria, DNSH and SS requirements
Through its sustainability tech platform, Clarity AI can scalably assess >180,000 funds and >30,000 organizations. For this report, Clarity AI selected a subset of its universe where it takes a deeper look into the EU Taxonomy alignment for more than 31,000 funds globally. Clarity AI focused the analysis on the parent funds (independent of the asset classes) of equity-only funds for which it has enough characterization of the fund (e.g., assets under management, description, etc.). For the sake of comparison, they cover a broad range of regions, sectors and strategies.
1 As per the EU Taxonomy’s methodology of calculating alignment: Use the weighted average of the percent green revenues by company, which is based on the weights within a portfolio
2 As per the European Commission study published in June 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005718/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
